Korean J Gastroenterol.  2024 Mar;83(3):131-132. 10.4166/kjg.2024.009.

Association between Helicobacter Infection and the Efficacy of Cancer Immunotherapy

• Kang SH

• KMID: 2554268
• DOI: http://doi.org/10.4166/kjg.2024.009

Reference

1. Gong X, Shen L, Xie J, Liu D, Xie Y, Liu D. 2023; Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis. Helicobacter. 28:e13011. DOI: 10.1111/hel.13011. PMID: 37661590.

2. Oster P, Vaillant L, Riva E, et al. 2022; Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 71:457–466. DOI: 10.1136/gutjnl-2020-323392. PMID: 34253574. PMCID: PMC8862014.

3. Ricci V, Giannouli M, Romano M, Zarrilli R. 2014; Helicobacter pylori gamma-glutamyl transpeptidase and its pathogenic role. World J Gastroenterol. 20:630–638. DOI: 10.3748/wjg.v20.i3.630. PMID: 24574736. PMCID: PMC3921472.

4. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. 2018; Tumor-Intrinsic PD-L1 signaling in cancer initiation, development and treatment: Beyond immune evasion. Front Oncol. 8:386. DOI: 10.3389/fonc.2018.00386. PMID: 30283733. PMCID: PMC6156376.

5. Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. 2021; The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 13:1–22. DOI: 10.1080/19490976.2021.1909459.

6. Cheng WY, Wu CY, Yu J. 2020; The role of gut microbiota in cancer treatment: friend or foe? Gut. 69:1867–1876. DOI: 10.1136/gutjnl-2020-321153. PMID: 32759302. PMCID: PMC7497589.

7. Oster P, Vaillant L, Riva E, McMillan B, et al. 2022; Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 71:457–466. DOI: 10.1136/gutjnl-2020-323392. PMID: 34253574. PMCID: PMC8862014.